Australia markets open in 8 hours 29 minutes

Chimerix, Inc. (CMRX)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
0.9050-0.0089 (-0.97%)
As of 11:29AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close0.9139
Bid0.7859 x 100
Ask1.0400 x 100
Day's range0.9000 - 0.9397
52-week range0.8800 - 1.5700
Avg. volume433,567
Market cap80.735M
Beta (5Y monthly)1.10
PE ratio (TTM)N/A
EPS (TTM)-0.9300
Earnings date02 May 2024 - 06 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    DURHAM, N.C., April 16, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) today announced that on April 10, 2024, the Compensation Committee of Chimerix’s Board of Directors granted inducement awards to four new employees of non-statutory stock options to purchase up to a total of 223,000 shares of Chimerix’s common stock. The Compensation Committee of Chimerix’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing rule

  • Simply Wall St.

    We Think Chimerix (NASDAQ:CMRX) Needs To Drive Business Growth Carefully

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • GlobeNewswire

    Chimerix Appoints Marc D. Kozin to Board of Directors

    Veteran Industry Executive Brings More Than 35 Years of Corporate Strategy ExperienceDURHAM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the appointment of Marc D. Kozin as the newest member of the Company’s Board of Directors. In addition, Patrick Machado has announced his retirement from the Chimerix Board effe